To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

New study reveals potential cognitive benefits of Shingrix vaccine. The shingles shot may offer protection against dementia, especially in women.

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...

Sareen, PharmDMedically reviewed by Gurdeep S. Sareen, PharmD The second dose of Shingrix (recombinant zoster vaccine) may cause side effects that are worse than the first. The second dose is ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

Shingrix was hit hard in the first quarter as a result of the prioritisation of COVID-19 vaccination programmes in the US and other markets, with sales dropping almost 50% to £327 million, but ...

Some studies have also identified potential associations with dementia. The $1.7 million study, funded by GlaxoSmithKline (GSK), which makes Shingrix, will allow Harris to emulate two target trials ...

Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit ...

Shingrix grew 19% to £833 million in the quarter, backed up by solid performances for meningitis vaccines Bexsero and Menveo, which rose 34% to £218 million and 40% to £59 million, respectively.

GSK PLC (GSK) reports robust year-to-date sales growth, driven by Specialty Medicines, while navigating vaccine sales ...

Shingles. The CDC recommends all healthy adults 50 and older get two doses of Shingrix, the newest shingles vaccine. You should get the shots 2 to 6 months apart. It’s much more effective than ...